Individualized Obesity Pharmacotherapy

PHASE3CompletedINTERVENTIONAL
Enrollment

193

Participants

Timeline

Start Date

December 11, 2017

Primary Completion Date

May 26, 2022

Study Completion Date

May 26, 2022

Conditions
Obesity
Interventions
DRUG

Phentermine-Topiramate

Extended Release at dose of 7.5/46 mg oral daily

DRUG

Liraglutide

dose of 3 mg subcutaneous daily

DRUG

Naltrexone/bupropion

Oral naltrexone extended-release/bupropion extended-release at dose of 32/360 mg oral daily (divided in 2 tables in morning and 2 tablets in evening)

DRUG

Phentermine

15-37.5 mg oral daily

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT03374956 - Individualized Obesity Pharmacotherapy | Biotech Hunter | Biotech Hunter